US 2002/0172662 A1Published application

Combination therapy (temozolomide and alpha-IFN) for advanced cancer

AssigneeSchering Corporation

InventorMargaret H. Dugan

Life of this patent

Estimating the term…

Abstract

There is disclosed a method for treating advanced cancer in patients in need of such treating. Temozolomide and alpha interferon are administered in combination in amounts sufficient to achieve a clinical response.

Claims21

Dependent claims

A method for treating advanced cancer in patients in need of such treating comprising administering temozolomide and alpha interferon in amounts sufficient to achieve a clinical response.

Dependencies are inferred from the claim text.

Facts

Application: 10/134,183Filed 26 Apr 2002
Priority: 4 Oct 1995
Published: 21 Nov 2002
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 38/212
Interferons [IFN]: iFN-alpha
A61K 9/4858
Filling excipients; Inactive ingredients: organic compounds
A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Family

Application60/006,233Us provisional application · filed 4 Oct 1995
Application08/721,777Continuation · filed 25 Sep 1996
Application10/134,183Continuation · filed 26 Apr 2002
US 7,294,332 B2Related patent
US 2002/0172662 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results